Related references
Note: Only part of the references are listed.ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
Priya Kumthekar et al.
CLINICAL CANCER RESEARCH (2020)
Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads
Gemma E. Mudd et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Overview and Current Status of Peptide Receptor Radionuclide Therapy
David L. Bushnell et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2020)
Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer
Levente E. Dokus et al.
PHARMACEUTICS (2020)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin
Parisa Yousefpour et al.
SMALL (2019)
Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety
Rongjun He et al.
MOLECULES (2019)
Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide
Lucia Feni et al.
BIOCONJUGATE CHEMISTRY (2019)
Polatuzumab Vedotin: First Global Approval
Emma D. Deeks
DRUGS (2019)
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Kenji Tamura et al.
LANCET ONCOLOGY (2019)
Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice
Ivan Randelovic et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Antibody-drug conjugates for cancer
Cindy H. Chau et al.
LANCET (2019)
Targeting Triple Negative Breast Cancer Cells with Novel Cytotoxic Peptide-Doxorubicin Conjugates
Elmira Ziaei et al.
BIOCONJUGATE CHEMISTRY (2019)
Transferrin Receptor Targeted Cellular Delivery of Doxorubicin Via a Reduction-Responsive Peptide-Drug Conjugate
Songtao Li et al.
PHARMACEUTICAL RESEARCH (2019)
Development of bioactive gemcitabine-D-Lys6-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile
Nisar Sayyad et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Type of pH sensitive linker reveals different time-dependent intracellular localization, in vitro and in vivo efficiency in alpha-fetoprotein receptor targeted doxorubicin conjugate
M. Mollaev et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2019)
Cleavable linkers in antibody-drug conjugates
Jonathan D. Bargh et al.
CHEMICAL SOCIETY REVIEWS (2019)
Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery
Sabine Schuster et al.
BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY (2018)
On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site
Eirinaios I. Vrettos et al.
BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY (2018)
Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer
Yiwen You et al.
DRUG DELIVERY (2018)
Synthesis and photodynamic activities of integrin-targeting silicon(IV) phthalocyanine-cRGD conjugates
Bi-Yuan Zheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
A comparative study of the antitumor efficacy of peptide-doxorubicin conjugates with different linkers
Yanqin Liang et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate
Ahmed F. Salem et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Challenges and new frontiers in analytical characterization of antibody-drug conjugates
Anil Wagh et al.
MABS (2018)
Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design
Pamela A. Trail et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas
Jun Gong et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification
Sabine Schuster et al.
PHARMACEUTICS (2018)
Sacituzumab govitecan: an antibody-drug conjugate
Sheena Sahota et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Breast Cancer Targeting Peptide Binds Keratin 1: A New Molecular Marker for Targeted Drug Delivery to Breast Cancer
Rania Soudy et al.
MOLECULAR PHARMACEUTICS (2017)
Influence of Molecular size on the clearance of antibody fragments
Zhe Li et al.
PHARMACEUTICAL RESEARCH (2017)
Targeting Legumain As a Novel Therapeutic Strategy in Cancers
Chun-Wai Mai et al.
CURRENT DRUG TARGETS (2017)
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip Gotwals et al.
NATURE REVIEWS CANCER (2017)
Peptide-drug conjugates as effective prodrug strategies for targeted delivery
Yin Wang et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
ANG1005 for breast cancer brain metastases: correlation between 18F-FLT-PET after first cycle and MRI in response assessment
C. C. O'Sullivan et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer
Yuan Sheng et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Antibody-drug conjugates for cancer therapy
Anish Thomas et al.
LANCET ONCOLOGY (2016)
Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine
Bridget A. Quinn et al.
ONCOTARGET (2016)
Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications
Sharmila Banerjee et al.
CHEMICAL REVIEWS (2015)
Novel delivery approaches for cancer therapeutics
Ashim K. Mitra et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Organic Carbamates in Drug Design and Medicinal Chemistry
Arun K. Ghosh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M. Goldenberg et al.
ONCOTARGET (2015)
First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma A Phase 2b Randomized Clinical Trial
Sant P. Chawla et al.
JAMA ONCOLOGY (2015)
Long-Term Stabilization of Maleimide-Thiol Conjugates
Shaun D. Fontaine et al.
BIOCONJUGATE CHEMISTRY (2015)
Pharmacokinetic study of aldoxorubicin in patients with solid tumors
Monica M. Mita et al.
INVESTIGATIONAL NEW DRUGS (2015)
Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy
L. Nathan Tumey et al.
BIOCONJUGATE CHEMISTRY (2014)
GnRH-Gemcitabine Conjugates for the Treatment of Androgen-Independent Prostate Cancer: Pharmacokinetic Enhancements Combined with Targeted Drug Delivery
Theodoros Karampelas et al.
BIOCONJUGATE CHEMISTRY (2014)
Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates
Robert P. Lyon et al.
NATURE BIOTECHNOLOGY (2014)
Novel Peptide-Doxorubucin Conjugates for Targeting Breast Cancer Cells Including the Multidrug Resistant Cells
Rania Soudy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Synthesis of Peptide Radiopharmaceuticals for the Therapy and Diagnosis of Tumor Diseases
Mazen Jamous et al.
MOLECULES (2013)
The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance?
S. Casey Laizure et al.
PHARMACOTHERAPY (2013)
Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors
Razelle Kurzrock et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The Legumain Protease-Activated Auristatin Prodrugs Suppress Tumor Growth and Metastasis without Toxicity
Krishna Mohan Bajjuri et al.
CHEMMEDCHEM (2011)
Anthracycline-GnRH derivative bioconjugates with different linkages: Synthesis, in vitro drug release and cytostatic effect
Pascal Schlage et al.
JOURNAL OF CONTROLLED RELEASE (2011)
Somatostatin Receptor-Targeted Anti-Cancer Therapy
Li-Chun Sun et al.
CURRENT DRUG DELIVERY (2011)
Qualitative structure-metabolism relationships in the hydrolysis of carbamates
Federica Vacondio et al.
DRUG METABOLISM REVIEWS (2010)
A Novel Antitumor Prodrug Platform Designed to Be Cleaved by the Endoprotease Legumain
Liron Stern et al.
BIOCONJUGATE CHEMISTRY (2009)
Glutathione: Overview of its protective roles, measurement, and biosynthesis
Henry Jay Forman et al.
MOLECULAR ASPECTS OF MEDICINE (2009)
Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2
A. Regina et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Modulating paclitaxel bioavailability for targeting prostate cancer
Srinivas K. Kumar et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials
Felix Kratz
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Prodrugs of anthracyclines in cancer chemotherapy
F Kratz et al.
CURRENT MEDICINAL CHEMISTRY (2006)
EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics
RC Ireton et al.
CURRENT CANCER DRUG TARGETS (2005)
A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate
G Di Stefano et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Acetals as pH-sensitive linkages for drug delivery
ER Gillies et al.
BIOCONJUGATE CHEMISTRY (2004)
Effects of camptothecin conjugated to a somatostatin analog vector on growth of tumor cell lines in culture and related tumors in rodents
LC Sun et al.
DRUG DELIVERY (2004)
Differential regulation of EphA2 in normal and malignant cells
J Walker-Daniels et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Polyacetal-doxorubicin conjugates designed for pH-dependent degradation
R Tomlinson et al.
BIOCONJUGATE CHEMISTRY (2003)
Share Paper
